Clinical Pharmacology of Glucagon.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
07 Jun 2024
07 Jun 2024
Historique:
received:
01
03
2024
accepted:
26
05
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
7
6
2024
Statut:
aheadofprint
Résumé
Glucagon was discovered about a hundred years ago and its role in health and disease is under continuous investigation. Glucagon is a counter regulatory hormone secreted by alpha cells of the pancreas in response to multiple stimuli. Although some of glucagon's actions and its clinical application have been described, clinical experience with glucagon has been historically overshadowed by that of insulin. To date, the role of glucagon's actions in pharmacotherapy has been under explored. Glucagon plays a considerable role as a hormonal regulator via its known actions on the liver. The rise in obesity and diabetes mellitus prevalence is bringing focus to glucagon's known physiological roles and possible clinical applications. Six glucagon products and a glucagon analog are approved for use in the United States. Clinical pharmacology studies provide crucial support of glucagon's actions as evident from comprehensive pharmacokinetics and pharmacodynamics evaluations in humans. Here, we briefly describe the established physiological role of glucagon in humans and its known relationship with disease. We later summarize the clinical pharmacology of available glucagon products with different routes of administration.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Clinical Pharmacology & Therapeutics © 2024 American Society for Clinical Pharmacology and Therapeutics.
Références
Kimball, C.P. & Murlin, J.R. Aqueous extracts of pancreas. III. Some precipitation reactions of insulin. J. Biol. Chem. 58, 337–346 (1923).
MacDonald, P.E. & Rorsman, P. Metabolic messengers: glucagon. Nat. Metab. 5, 186–192 (2023).
Scheen, A.J. & Lefebvre, P.J. Glucagon, from past to present: a century of intensive research and controversies. Lancet Diabetes Endocrinol. 11, 129–138 (2023).
FDA. Drug Approval Package: GVOKE INJECTION <https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212097Orig1s000TOC.cfm> (2019).
Graf, C.J., Woodworth, J.R., Seger, M.E., Holcombe, J.H., Bowsher, R.R. & Lynch, R. Pharmacokinetic and glucodynamic comparisons of recombinant and animal‐source glucagon after IV, IM, and SC injection in healthy volunteers. J. Pharm. Sci. 88, 991–995 (1999).
Pieber, T.R., Aronson, R., Christiansen, M.P., Bode, B., Junaidi, K. & Conoscenti, V. Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready‐to‐use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin‐induced severe hypoglycaemia in adults with type 1 diabetes. Diabetes Obes. Metab. 24, 1394–1397 (2022).
Suico, J.G. et al. Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin‐induced Hypoglycaemia: a randomised, open‐label, crossover study. Diabetes Ther 11, 1591–1603 (2020).
Sherr, J.L. et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care 39, 555–562 (2016).
FDA. US FDA Drug Approval Package: ZEGALOGUE <https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000TOC.cfm> (2021).
Hovelmann, U. et al. Pharmacokinetic and Pharmacodynamic characteristics of Dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care 41, 531–537 (2018).
Battelino, T. et al. Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: results of a phase 3, randomized controlled trial. Pediatr. Diabetes 22, 734–741 (2021).
Holst, J.J., Wewer Albrechtsen, N.J., Pedersen, J. & Knop, F.K. Glucagon and amino acids are linked in a mutual feedback cycle: The liver‐alpha‐cell axis. Diabetes 66, 235–240 (2017).
Ryan, A.T. et al. Effects of intraduodenal lipid and protein on gut motility and hormone release, glycemia, appetite, and energy intake in lean men. Am. J. Clin. Nutr. 98, 300–311 (2013).
Winther‐Sorensen, M., Holst, J.J. & Wewer Albrechtsen, N.J. The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease. Curr. Opin. Lipidol. 34, 27–31 (2023).
Capozzi, M.E., D'Alessio, D.A. & Campbell, J.E. The past, present, and future physiology and pharmacology of glucagon. Cell Metab. 34, 1654–1674 (2022).
Knop, F.K. et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes. Metab. 14, 500–510 (2012).
Committee, A.D.A.P.P. 6. Glycemic goals and hypoglycemia: standards of Care in Diabetes—2024. Diabetes Care 47, S111–S125 (2023).
Pedersen‐Bjergaard, U. & Thorsteinsson, B. Reporting severe hypoglycemia in type 1 diabetes: facts and pitfalls. Curr. Diab. Rep. 17, 131 (2017).
Pontiroli, A.E., Alberetto, M. & Pozza, G. Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br. Med. J. 287, 462–463 (1983).
Pontiroli, A.E., Calderara, A., Pajetta, E., Alberetto, M. & Pozza, G. Intranasal glucagon as remedy for hypoglycemia. Studies in healthy subjects and type I diabetic patients. Diabetes Care 12, 604–608 (1989).
Boido, A., Ceriani, V. & Pontiroli, A.E. Glucagon for hypoglycemic episodes in insulin‐treated diabetic patients: a systematic review and meta‐analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetol. 52, 405–412 (2015).
Pontiroli, A.E. & Tagliabue, E. Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta‐analysis. Acta Diabetol. 57, 743–749 (2020).
Kaur, J. & Seaquist, E.R. Translational aspects of glucagon: current use and future prospects. J. Endocrinol. 257, e220278 (2023).